ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Permissions
Right arrowRequest Permissions
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Philit, F
Right arrow Articles by Cordier, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Philit, F
Right arrow Articles by Cordier, J.
Eur Respir J 1995; 8: 551-558
Copyright © ERS Journals Ltd 1995

Original Articles

Post-transplant obstructive lung disease ("bronchiolitis obliterans"): a clinical comparative study of bone marrow and lung transplant patients

F Philit, T Wiesendanger, E Archimbaud, JF Mornex, J Brune, and JF Cordier

Patients at a single pulmonary centre who developed obstructive lung disease after bone marrow transplantation (BMT) and lung transplantation (LT) were studied, in order to compare the clinical expression of post-transplant obstructive lung disease (PTOLD) (bronchiolitis obliterans) in these two conditions, which have so far been studied separately. Nine out of 179 patients surviving more than 100 days after BMT (5%) and 9 out of 44 patients surviving more than 100 days after LT (20%) developed post-transplant obstructive lung disease. This was defined by an irreversible airflow obstruction, as characterized by a forced expiratory volume in one second divided by forced vital capacity (FEV1/FVC) of less than 70%, and a FEV1 of less than 70% of predicted value. The mean interval between transplantation and the diagnosis of post-transplant obstructive lung disease was 262 days and 217 days for BMT and LT patients, respectively. In all cases, pulmonary symptoms consisted of dyspnoea and progressively productive cough. Bronchial dilatation on high-resolution computed tomography scans was the main imaging feature present in both groups of patients at the onset of post-transplant obstructive lung disease. The mean FEV1/FVC ratio was 51 and 54% for BMT and LT patients, respectively. All BMT and LT patients had normal transfer coefficient. Clinical chronic graft-versus-host disease was present in all BMT patients before or concurrent with the onset of post-transplant obstructive lung disease, and all LT patients had presented at least one episode of acute lung rejection.(ABSTRACT TRUNCATED AT 250 WORDS)


This article has been cited by other articles:


Home page
 JAMAHome page
K. M. Williams, J. W. Chien, M. T. Gladwin, and S. Z. Pavletic
Bronchiolitis Obliterans After Allogeneic Hematopoietic Stem Cell Transplantation
JAMA, July 15, 2009; 302(3): 306 - 314.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
G. Devouassoux, V. Cottin, H. Liote, E. Marchand, I. Frachon, A. Schuller, F. Bejui-Thivolet, J-F. Cordier, and the Groupe d'Etudes et de Recherche sur les Maladi
Characterisation of severe obliterative bronchiolitis in rheumatoid arthritis
Eur. Respir. J., May 1, 2009; 33(5): 1053 - 1061.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
J.-F. Cordier
Challenges in pulmonary fibrosis {middle dot} 2 : Bronchiolocentric fibrosis
Thorax, July 1, 2007; 62(7): 638 - 649.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
A. O. Soubani and J. P. Uberti
Bronchiolitis obliterans following haematopoietic stem cell transplantation
Eur. Respir. J., May 1, 2007; 29(5): 1007 - 1019.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
L. H. S. Tomas, F. R. Loberiza Jr, J. P. Klein, P. M. Layde, R. J. Lipchik, J. D. Rizzo, C. N. Bredeson, and M. M. Horowitz
Risk Factors for Bronchiolitis Obliterans in Allogeneic Hematopoietic Stem-Cell Transplantation for Leukemia
Chest, July 1, 2005; 128(1): 153 - 161.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
D. H. Bryant
Obliterative bronchiolitis in haematopoietic stem cell transplantation: can it be treated?
Eur. Respir. J., March 1, 2005; 25(3): 402 - 405.
[Full Text] [PDF]

Home page
 Br. J. Radiol.Home page
D Beckett and J Olliff
Non-infectious manifestations of stem cell transplantation
Br. J. Radiol., March 1, 2005; 78(927): 272 - 281.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
M.B. Lund, L. Brinch, J. Kongerud, and J. Boe
Lung function 5 yrs after allogeneic bone marrow transplantation conditioned with busulphan and cyclophosphamide
Eur. Respir. J., June 1, 2004; 23(6): 901 - 905.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
E. Sakaida, C. Nakaseko, A. Harima, A. Yokota, R. Cho, Y. Saito, and M. Nishimura
Late-onset noninfectious pulmonary complications after allogeneic stem cell transplantation are significantly associated with chronic graft-versus-host disease and with the graft-versus-leukemia effect
Blood, December 1, 2003; 102(12): 4236 - 4242.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
J. W. Chien, P. J. Martin, T. A. Gooley, M. E. Flowers, S. R. Heckbert, W. G. Nichols, and J. G. Clark
Airflow Obstruction after Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation
Am. J. Respir. Crit. Care Med., July 15, 2003; 168(2): 208 - 214.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
C. K. Kim, S. W. Kim, J. S. Kim, Y. Y. Koh, A. H. Cohen, R. R. Deterding, and C. W. White
Bronchiolitis Obliterans in the 1990s in Korea and the United States
Chest, October 1, 2001; 120(4): 1101 - 1106.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1995 by the European Respiratory Society.